PDCD1LG2 and histiocytic sarcoma: Checkpoint inhibitors may also be promising drugs for treating HS, as suggested by the differential expression of numerous immune checkpoints, including CD274 (PDL1) and PDCD1LG2 (PDL2) (Table 1), in this study.